实验室、动物试验和临床研究表明，干扰素γ（IFN-γ）对肝和肺纤维化有抑制作用。国内外学者报告用IFN-γ治疗各种原因引起的肝纤维化有效，临床症状明显改善，肝纤维化程度明显减轻。IFN-γ治疗特发性肺纤维化的初步结果显示，治疗后各种生物学指标有所改善，临床效果各家报道不一，多数学者认为IFN-γ治疗能降低病死率，对病情轻到中度的患者效果较好，用药时间应在1年以上。

Animal experiments and clinical studies show the inhibiting effect of IFN-γ on hepatic and pulmonary fibrosis. Numerous research evidence suggests that IFN-γ is an effective therapy for hepatic fibrosis in improving clinical symptoms, and relieving hepatic fibrosis. Preliminary study results of IFN-γ for the treatment of idiopathic pulmonary fibrosis (IPF) show that various biomarkers are improved after IFN-γ therapy, and the case mortality is lowered. The therapeutic efficacy of IFN-γ has been demonstrated to be better in mild and moderate patients with IPF. The duration of IFN-γ therapy should be more than one year.